I 
110TH CONGRESS 
1ST SESSION 
H. R. 962 
To amend the Federal Food, Drug, and Cosmetic Act to preserve the effective-
ness of medically important antibiotics used in the treatment of human 
and animal diseases. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 8, 2007 
Ms. SLAUGHTER introduced the following bill; which was referred to the 
Committee on Energy and Commerce 
A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
preserve the effectiveness of medically important anti-
biotics used in the treatment of human and animal dis-
eases. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Preservation of Antibiotics for Medical Treatment Act of 
2007’’. 
(b) TABLE OF CONTENTS.—The table of contents of 
this Act is as follows: 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
Sec. 1. Short title; table of contents. 
Sec. 2. Findings. 
Sec. 3. Purpose. 
TITLE I—SAFETY OF CRITICAL ANTIMICROBIAL ANIMAL DRUGS 
Sec. 101. Proof of safety of critical antimicrobial animal drugs. 
TITLE II—USE OF CRITICAL ANTIMICROBIAL ANIMAL DRUGS IN 
AGRICULTURE 
Sec. 201. Collection of data on critical antimicrobial animal drugs. 
SEC. 2. FINDINGS. 
The Congress finds that— 
(1)(A) in January 2001, a Federal interagency 
task force released an action plan to address the 
continuing decline in effectiveness of antibiotics 
against common bacterial infections, referred to as 
antibiotic resistance; 
(B) the task force determined that antibiotic re-
sistance is a growing menace to all people and poses 
a serious threat to public health; and 
(C) the task force cautioned that if current 
trends continue, treatments for common infections 
will become increasingly limited and expensive, and, 
in some cases, nonexistent; 
(2) antibiotic resistance, resulting in a reduced 
number of effective antibiotics, may significantly im-
pair the ability of the United States to respond to 
terrorist attacks involving bacterial infections or a 
large influx of hospitalized patients; 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
(3)(A) any overuse or misuse of antibiotics con-
tributes to the spread of antibiotic resistance, wheth-
er in human medicine or in agriculture; and 
(B) recognizing the public health threat caused 
by antibiotic resistance, Congress took several steps 
to curb antibiotic overuse in human medicine 
through amendments to the Public Health Service 
Act (42 U.S.C. 201 et seq.) made by section 102 of 
the Public Health Threats and Emergencies Act 
(Public Law 106–505, title I; 114 Stat. 2315), but 
has not yet addressed antibiotic overuse in agri-
culture; 
(4) in a March 2003 report, the National Acad-
emy of Sciences stated that— 
(A) a decrease in antimicrobial use in 
human medicine alone will have little effect on 
the current situation; and 
(B) substantial efforts must be made to 
decrease inappropriate overuse in animals and 
agriculture; 
(5)(A) an estimated 70 percent of the anti-
biotics and other antimicrobial drugs used in the 
United States are fed to farm animals for nonthera-
peutic purposes, including— 
(i) growth promotion; and 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
(ii) compensation for crowded, unsanitary, 
and stressful farming and transportation condi-
tions; and 
(B) unlike human use of antibiotics, these non-
therapeutic uses in animals typically do not require 
a prescription; 
(6)(A) many scientific studies confirm that the 
nontherapeutic use of antibiotics in agricultural ani-
mals contributes to the development of antibiotic-re-
sistant bacterial infections in people; 
(B) the periodical entitled ‘‘Clinical Infectious 
Diseases’’ published a report in June 2002, based on 
a 2-year review by experts in human and veterinary 
medicine, public health, microbiology, biostatistics, 
and risk analysis, of more than 500 scientific studies 
on the human health impacts of antimicrobial use in 
agriculture; and 
(C) the report recommended that antimicrobial 
agents should no longer be used in agriculture in the 
absence of disease, but should be limited to therapy 
for diseased individual animals and prophylaxis 
when disease is documented in a herd or flock; 
(7) the United States Geological Survey re-
ported in March 2002 that— 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
(A) antibiotics were present in 48 percent 
of the streams tested nationwide; and 
(B) almost half of the tested streams were 
downstream from agricultural operations; 
(8) an April 1999 study by the General Ac-
counting Office concluded that resistant strains of 3 
microorganisms that cause food-borne illness or dis-
ease in humans—Salmonella, Campylobacter, and E. 
coli—are linked to the use of antibiotics in animals; 
(9)(A) in January 2003, Consumer Reports 
published test results on poultry products bought in 
grocery stores nationwide showing disturbingly high 
levels of Campylobacter and Salmonella bacteria that 
were resistant to antibiotics used to treat food-borne 
illnesses; and 
(B) further studies showed similar results in 
other meat products; 
(10) in October 2001, the New England Jour-
nal of Medicine published an editorial urging a ban 
on nontherapeutic use of medically important anti-
biotics in animals; 
(11)(A) in 1999, the European Union banned 
the practice of feeding medically important anti-
biotics to animals other than for disease treatment 
or control, and prior to that, individual European 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
countries had banned the use of specific antibiotics 
in animal feed; and 
(B) those countries have experienced no signifi-
cant impact on animal health or productivity, food 
safety, or meat prices, and more importantly, levels 
of resistant bacteria have declined sharply; 
(12) in 1998, the National Academy of Sciences 
noted that antibiotic-resistant bacteria generate a 
minimum of $4,000,000,000 to $5,000,000,000 in 
costs to United States society and individuals yearly; 
(13) a year later, the National Academy of 
Sciences estimated that eliminating the use of all 
antibiotics as feed additives would cost each Amer-
ican consumer less than $5 to $10 per year; 
(14) the American Medical Association, the 
American Public Health Association, the National 
Association of County and City Health Officials, and 
the National Campaign for Sustainable Agriculture, 
are among the more than 300 organizations rep-
resenting health, consumer, agricultural, environ-
mental, humane, and other interests that support 
enactment of legislation to phase out nontherapeutic 
use in farm animals of medically important anti-
biotics; 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
(15) the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 301 et seq.)— 
(A) requires that all drugs be shown to be 
safe before the drugs are approved; and 
(B) places the burden on manufacturers to 
account for health consequences and prove safe-
ty; 
(16)(A) the Food and Drug Administration re-
cently modified the drug approval process for anti-
biotics to recognize the development of resistant bac-
teria as an important aspect of safety; 
(B) however, most antibiotics currently used in 
animal production systems for nontherapeutic pur-
poses were approved before the Food and Drug Ad-
ministration began giving in-depth consideration to 
resistance during the drug-approval process; and 
(C) the Food and Drug Administration has not 
established a schedule for reviewing those existing 
approvals; and 
(17) certain non-routine uses of antibiotics in 
animal agriculture are legitimate to prevent animal 
disease; and 
(18)(A) an April 2004 study by the General Ac-
counting Office concluded that Federal agencies do 
not collect the critical data on antibiotic use in ani-
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
mals that they need to support research on human 
health risks; and 
(B) the report recommends that the Depart-
ment of Agrigulture and the Department of Health 
and Human Services develop and implement a plan 
to collect data on antibiotic use in animals. 
SEC. 3. PURPOSE. 
The purpose of this Act is to preserve the effective-
ness of medically important antibiotics used in the treat-
ment of human and animal diseases by phasing out use 
of certain antibiotics for nontherapeutic purposes in food- 
producing animals. 
TITLE I—SAFETY OF CRITICAL 
ANTIMICROBIAL ANIMAL DRUGS 
SEC. 101. PROOF OF SAFETY OF CRITICAL ANTIMICROBIAL 
ANIMAL DRUGS. 
(a) DEFINITIONS.—Section 201 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 321) is amended by 
adding at the end the following: 
‘‘(rr) CRITICAL ANTIMICROBIAL ANIMAL DRUG.— 
The term ‘critical antimicrobial animal drug’ means a 
drug that— 
‘‘(1) is intended for use in food-producing ani-
mals; and 
‘‘(2) is composed wholly or partly of— 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
‘‘(A) any kind of penicillin, tetracycline, 
macrolide, 
lincosamide, 
streptogramin, 
aminoglycoside, or sulfonamide; or 
‘‘(B) any other drug or derivative of a 
drug that is used in humans or intended for use 
in humans to treat or prevent disease or infec-
tion caused by microorganisms. 
‘‘(ss) NONTHERAPEUTIC USE.—The term ‘nonthera-
peutic use’, with respect to a critical antimicrobial animal 
drug, means any use of the drug as a feed or water addi-
tive for an animal in the absence of any clinical sign of 
disease in the animal for growth promotion, feed effi-
ciency, weight gain, routine disease prevention, or other 
routine purpose.’’. 
(b) APPLICATIONS PENDING OR SUBMITTED AFTER 
ENACTMENT.—Section 512(d)(1) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 360b(d)(1)) is amend-
ed— 
(1) in the first sentence— 
(A) in subparagraph (H), by striking ‘‘or’’ 
at the end; 
(B) by redesignating subparagraph (I) as 
subparagraph (J); and 
(C) by inserting after subparagraph (H) 
the following: 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
‘‘(I) with respect to a critical antimicrobial 
animal drug or a drug of the same chemical 
class as a critical antimicrobial animal drug, 
the applicant has failed to demonstrate that 
there is a reasonable certainty of no harm to 
human health due to the development of anti-
microbial resistance that is attributable, in 
whole or in part, to the nontherapeutic use of 
the drug; or’’; and 
(2) in the second sentence, by striking ‘‘(A) 
through (I)’’ and inserting ‘‘(A) through (J)’’. 
(c) PHASED ELIMINATION
OF NONTHERAPEUTIC 
USE IN ANIMALS OF CRITICAL ANTIMICROBIAL ANIMAL 
DRUGS IMPORTANT FOR HUMAN HEALTH.—Section 512 
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360b) is amended by adding at the end the following: 
‘‘(q) PHASED ELIMINATION OF NONTHERAPEUTIC 
USE IN ANIMALS OF CRITICAL ANTIMICROBIAL ANIMAL 
DRUGS IMPORTANT FOR HUMAN HEALTH.— 
‘‘(1) APPLICABILITY.—This subsection applies 
to the nontherapeutic use in a food-producing ani-
mal of a drug— 
‘‘(A)(i) that is a critical antimicrobial ani-
mal drug; or 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
‘‘(ii) that is of the same chemical class as 
a critical antimicrobial animal drug; and 
‘‘(B)(i) for which there is in effect an ap-
proval of an application or an exemption under 
subsection (b), (i), or (j) of section 505; or 
‘‘(ii) that is otherwise marketed for use. 
‘‘(2) WITHDRAWAL.—The Secretary shall with-
draw the approval of a nontherapeutic use in food- 
producing animals described in paragraph (1) on the 
date that is 2 years after the date of enactment of 
this subsection unless— 
‘‘(A) before the date that is 2 years after 
the date of the enactment of this subsection, 
the Secretary makes a final written determina-
tion that the holder of the approved application 
has demonstrated that there is a reasonable 
certainty of no harm to human health due to 
the development of antimicrobial resistance that 
is attributable in whole or in part to the non-
therapeutic use of the drug; or 
‘‘(B) before the date specified in subpara-
graph (A), the Secretary makes a final written 
determination under this subsection, with re-
spect to a risk analysis of the drug conducted 
by the Secretary and other relevant informa-
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
TITLE 
II—USE 
OF 
CRITICAL 
ANTIMICROBIAL 
ANIMAL 
DRUGS IN AGRICULTURE 
SEC. 201. COLLECTION OF DATA ON CRITICAL ANTI-
MICROBIAL ANIMAL DRUGS. 
(a) IN GENERAL.—Chapter V of the Federal Food, 
Drug, and Cosmetic Act is amended by inserting after sec-
tion 512 (21 U.S.C. 360b) the following: 
‘‘SEC. 512A. COLLECTION OF DATA ON CRITICAL ANTI-
MICROBIAL ANIMAL DRUGS. 
‘‘(a) IN GENERAL.—Not later than July 1 of each 
year, a manufacturer of a critical antimicrobial animal 
drug or an animal feed for food-producing animals bearing 
or containing a critical antimicrobial animal drug shall 
submit to the Secretary a report, in such form as the Sec-
retary shall require, containing information on the sales 
during the previous calendar year of the critical anti-
microbial animal drug or the animal feed. 
‘‘(b) INFORMATION TO BE INCLUDED.—A report 
under subsection (a) shall— 
‘‘(1) state separately the quantity of the critical 
antimicrobial animal drug, including such quantity 
in animal feed bearing or containing the critical 
antimicrobial drug, sold for each kind of food-pro-
ducing animal; 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS
‘‘(2) describe the claimed purpose of use for the 
drug for each kind of food-producing animal as 
being for growth promotion, weight gain, feed effi-
ciency, disease prevention, disease control, disease 
treatment, or another purpose; and 
‘‘(3) describe the dosage form of the drug. 
‘‘(c) PUBLICATION.— 
‘‘(1) IN GENERAL.—The Secretary shall make 
the information submitted under subsection (a) 
available to the public not less than annually. 
‘‘(2) PROTECTION OF CONFIDENTIALITY.—The 
Secretary may aggregate information, if necessary, 
so as to avoid disclosure under paragraph (1) of con-
fidential business information.’’. 
(b) VIOLATION.—Subsection (e) of section 301 of the 
Federal Food, Drug and Cosmetic Act (21 U.S.C. 331(e)) 
is amended by striking ‘‘515(f)’’ and inserting ‘‘512A, 
515(f)’’. 
(c) EFFECTIVE DATE.—The amendments made by 
this section shall take effect on January 1, 2008. 
Æ 
VerDate Aug 31 2005 
23:56 Feb 12, 2007
Jkt 059200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6301
E:\BILLS\H962.IH
H962
hmoore on PROD1PC68 with HMBILLS